Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 17:33:05 23/06/2026			Varia. 5j.	Varia. 1 janv.
19,32 ^USD	+3,45%		+9,18%	+23,66%

07/05	Monte Rosa Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/04	Monte Rosa Therapeutics présente au congrès annuel de l'AACR 2026 des données précliniques sur le potentiel de son dégradateur de colle moléculaire ciblant la cycline E1 (CCNE1) dans le traitement des tumeurs solides avec amplification de CCNE1	CI

Autres langues

02/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot
07/05	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
05/05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/04	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
17/03	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
17/03	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting
17/03	Monte Rosa Therapeutics, Inc. Announces Executive Changes
17/03	Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls
17/03	Monte Rosa Therapeutics: Q4 Earnings Snapshot
17/03	Monte Rosa Therapeutics : Corporate Presentation – March 2026
17/03	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M
17/03	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
16/03	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16/03	Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
16/03	Monte Rosa Therapeutics announces clinical supply agreement to support phase 2 trial evaluating MRT-2359 in combination with apalutamide for the treatment of metastatic castration-resistant prostate cancer
16/03	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
02/03	Monte Rosa Therapeutics Insider Sold Shares Worth $464,886, According to a Recent SEC Filing
26/02	Monte Rosa Therapeutics : Corporate Presentation – February 2026